Method of enhancing KSHV LANA1 immunogenicity
AssigneeUniversity of Pittsburg—Of the Commonwealth System of Higher Education
InventorsYuan Chang, Patrick S. Moore
Life of this patent
Estimating the term…
Abstract
An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein.
Claims6
A method of eliciting an immune response to Kaposi sarcoma associated herpes virus latency associated nuclear antigen (“KSHV LANA1”) in a patient comprising removing a cell from the patient, introducing into the cell a modified SEQ ID NO:
- 1 for eliciting a CTL immune response to LANA1, wherein the modified SEQ ID NO:
- 1 consists of a LANA1 amino acid sequence comprising one or more LANA1 T-cell epitopes, and wherein the LANA1 amino acid sequence is modified to exhibit increased CTL immune response as compared to wild-type LANA1 protein, and returning the cell to the patient, wherein the modified SEQ ID NO:
- 1 consists of the sequence of SEQ ID NO:
- 1 in which 20 to 98 amino acids between amino acids 330 and 428 are deleted.
A method of eliciting an immune response to Kaposi sarcoma associated herpes virus latency associated nuclear antigen (“KSHV LANA1”) in a patient comprising removing a cell from the patient, introducing into the cell a modified SEQ ID NO:
- 1 for eliciting a CTL immune response to LANA1, wherein the modified SEQ ID NO:
- 1 consists of a LANA1 amino acid sequence comprising one or more LANA1 T-cell epitopes, and wherein the LANA1 amino acid sequence is modified to exhibit increased CTL immune response as compared to wild-type LANA1 protein, and returning the cell to the patient, wherein the modified SEQ ID NO:
- 1 is modified by removing or replacing at least one amino acid between amino acid 330 and amino acid 428 of SEQ ID NO:
- 1, wherein
- the modified SEQ ID NO:
- 1 further comprises a protein destabilization domain, and the modified SEQ ID NO:
- 1 polypeptide exhibits increased proteasomal degradation as compared to wild-type LANA1 protein.
Dependencies are inferred from the claim text.